Full-Time

Director – Regulatory

Posted on 7/28/2025

Precision AQ

Precision AQ

501-1,000 employees

Data-driven drug access and launches

No salary listed

Remote in Australia

Remote

Category
Legal & Compliance (2)
,
Required Skills
Google Cloud Platform
Requirements
  • Post Graduate Degree, Bachelors degree, or equivalent experience, ideally in a scientific or healthcare discipline
  • 10+ years or more relevant regulatory affairs experience in CRO, Pharma, Biotech or related industry
  • Extensive and broad knowledge and experience of all aspects of drug development process, including subject matter expertise in regulations and guidelines (including but not limited to: NA, EMA, APAC, national authorities and IHC/GCP/GMP)
  • Proven track record of supporting client development activities leading regulatory pharmaceutical product development and managing complex regulatory clinical programs
  • Previous line management experience
  • Computer literacy (MS Office/ Office 365)
Responsibilities
  • Provide strategic, technical, and regulatory guidance to clients and team members in the area of clinical development of human medicinal products and drug development life cycle
  • Establish operational objectives and assignments for assigned team members
  • Track and report regulatory function metrics and key performance indicators
  • Oversee, review and provide strategic input on applications to Regulatory Authorities including, but not limited to, CTA/IND, annual reports, routine amendments, scientific advice/regulatory authority meetings, orphan designations, paediatric planning, and expedited pathways
  • As needed, review documents intended for submission to the Regulatory Authorities and/or Ethics Committees to ensure compliance with regulatory standards
  • Select, train, develop, coach and manage the performance of Regulatory Managers, ensuring the sharing of best practices across the team
  • Oversee resource allocation and utilization of Regulatory Managers
  • As needed, represent Global Regulatory Affairs at project team meetings with both external and internal customers and manage/oversee regulatory workflow between departments
  • Provide oversight to filing and study teams regarding regulations/guidelines and company SOPs to ensure successful and high-quality regulatory applications
  • Ensure budgets and plans meet corporate requirements
  • Provide ICH/GCP/Regulation guidance, advice and training to internal and external clients
  • Participate in developing, implementing, and maintaining the corporate quality initiatives across business units within Clinical Solutions/Precision for Medicine
  • Implement regulatory tools to support the department
  • Assist in developing, modifying and executing company policies that affect Regulatory Affairs and may impact other departments
  • Support QA audits and/or assign applicable team members to participate in audits
  • Establishes and maintains a high level of technical knowledge in the area of product development and international regulatory affairs. Interprets emerging regulatory requirements and collaborates in impact assessment and implementation
  • Supports Business Development in generation of customer focused, well-presented regulatory proposal content and budgets, partnering with other functional areas as required to define bid content, strategy, scope of work
Desired Qualifications
  • Advanced degree in medical or life sciences (MD, PhD, PharmD)/RAC (or equivalent) certification/Masters in Regulatory Sciences
  • Experience in functional management including experience in delegating while fostering cohesive team dynamics
  • Possesses understanding of financial management

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Emma Hawe and Yahya Shaikh hires strengthen AI and HEOR for EU biopharma expansion.
  • Oncology AET expansions optimize Value Based Care and formulary design amid payer shifts.
  • Works with all 30 top pharma firms, launching over 450 drugs across therapeutics.

What critics are saying

  • Phluence fails to cut costs, pharma reverts to Ashfield HUBs within 6-12 months.
  • New AET hires underperform, Syneos Health steals oncology launches in 12-24 months.
  • EU AI Act scrutiny halts Hawe-Shaikh services and cross-border revenue in 18-24 months.

What makes Precision AQ unique

  • Precision AQ unifies PRECISIONadvisors, PRECISIONheor, and Across Health for comprehensive access services.
  • Access Experience Team includes five BCOPs like Shraddha Kansagra for oncology payer strategies.
  • Phluence investment enables AI-driven agentic workflows replacing traditional HUB models.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Parental Leave

Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...

INACTIVE